Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

8HD8

Crystal structure of TMPRSS2 in complex with 212-148

Summary for 8HD8
Entry DOI10.2210/pdb8hd8/pdb
DescriptorTransmembrane protease serine 2 catalytic chain, CALCIUM ION, 4-carbamimidamidobenzoic acid, ... (6 entities in total)
Functional Keywordsinhibitor, complex, host, antiviral, antiviral protein, hydrolase
Biological sourceHomo sapiens (human)
More
Total number of polymer chains4
Total formula weight88482.52
Authors
Wang, H.,Liu, X.,Sun, L.,Yang, H. (deposition date: 2022-11-03, release date: 2023-12-13, Last modification date: 2024-06-19)
Primary citationWang, H.,Yang, Q.,Liu, X.,Xu, Z.,Shao, M.,Li, D.,Duan, Y.,Tang, J.,Yu, X.,Zhang, Y.,Hao, A.,Wang, Y.,Chen, J.,Zhu, C.,Guddat, L.,Chen, H.,Zhang, L.,Chen, X.,Jiang, B.,Sun, L.,Rao, Z.,Yang, H.
Structure-based discovery of dual pathway inhibitors for SARS-CoV-2 entry.
Nat Commun, 14:7574-7574, 2023
Cited by
PubMed Abstract: Since 2019, SARS-CoV-2 has evolved rapidly and gained resistance to multiple therapeutics targeting the virus. Development of host-directed antivirals offers broad-spectrum intervention against different variants of concern. Host proteases, TMPRSS2 and CTSL/CTSB cleave the SARS-CoV-2 spike to play a crucial role in the two alternative pathways of viral entry and are characterized as promising pharmacological targets. Here, we identify compounds that show potent inhibition of these proteases and determine their complex structures with their respective targets. Furthermore, we show that applying inhibitors simultaneously that block both entry pathways has a synergistic antiviral effect. Notably, we devise a bispecific compound, 212-148, exhibiting the dual-inhibition ability of both TMPRSS2 and CTSL/CTSB, and demonstrate antiviral activity against various SARS-CoV-2 variants with different viral entry profiles. Our findings offer an alternative approach for the discovery of SARS-CoV-2 antivirals, as well as application for broad-spectrum treatment of viral pathogenic infections with similar entry pathways.
PubMed: 37990007
DOI: 10.1038/s41467-023-42527-5
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.4 Å)
Structure validation

226707

PDB entries from 2024-10-30

PDB statisticsPDBj update infoContact PDBjnumon